C2orf49

Across TCGA pan-cancer cohorts, C2orf49 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C2orf49 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher C2orf49 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C2orf49 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

STAD, PRAD, and BLCA are the cancer types where C2orf49 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.089	0.657	<.001	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	DFS	Median	III,IV	1.000	0.270	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

C2orf49–STAD (DFS)

Open the STAD breakdown →